Proprotein convertases (PCs), such as PC1 and furin, are a ubiquitous super-family of evolutionarily conserved serine proteases responsible for mediating a diverse range of processing steps to generate active proteins and peptides within the cell. As premature protease activity can lead to inappropriate protein activation, sorting, or degradation, PC activity is stringently modulated by N-terminal propeptides that function as Intramolecular Chaperones (IMCs) to initially fold protease domains, and act as catalytic inhibitors. Although they share overlapping specificity, it is the ability of the IMC to act as an inhibitor of its cognate catalytic domain that directs the organelle- and pH-specific activation of PC1 and furin, allowing them to selectively cleave their substrates in compartment-specific manner in vivo. Mutations in IMCs of PC1 and furin underlie the aberrant activities seen in a range of endocrinopathies, including extreme obesity, abnormal glucose homeostasis, as well as cancer and heart disease. Despite devastating consequences on cellular homeostasis, the molecular and cellular determinants that modulate activation of PCs are poorly understood. Using an array of biochemical, biophysical, computational and molecular techniques, the goals of this proposal are to 1) determine how the IMC of PC1 acts as a pH sensor, and 2) develop specific inhibitors of PC1 activity.

Public Health Relevance

Defects impairing the activation or activity of PC1 and furin can lead to a wide spectrum of diseased states, including extreme obesity, abnormal glucose homeostasis, heart disease, and cancer. While it is known that the activation of pro-PC1 and pro-furin must be stringently regulated in a pH- and compartment-specific manner, the precise mechanisms of their control remain unclear. The relevance of this project to public health is that a more complete understanding of the spatiotemporal regulation of PC1 and furin is an essential component of treating and preventing endocrinopathies and heart disease through development of more effective therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
5F30DK096752-02
Application #
8707227
Study Section
Special Emphasis Panel (ZDK1-GRB-R (M1))
Program Officer
Castle, Arthur
Project Start
2013-08-01
Project End
2017-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
$47,676
Indirect Cost
Name
Oregon Health and Science University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239